Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

3I Group sees Q2 NAV jump

(Sharecast News) - Infrastructure and private equity investor 3i posted a jump in its second quarter net asset value, thanks in part to a foreign exchange tailwind. For the three months ending on 30 June, 3i reported a 6.6% rise in its Net Asset Value to reach 2,711.0p per share, helped by a foreign exchange translation impact of £392m, or 40p per share.

"We have started FY2026 well, with the Private Equity and Infrastructure portfolios trading in line with our expectations. The MPM transaction also provided further evidence of how our active asset management can lead to material value creation over time," 3i boss Simon Borrows said.

"Action had a good first half, with trading across the majority of its key financial metrics well ahead of the same period last year, and with notable milestones achieved, including its 3000th store and a very strong start from the first five stores in Switzerland."

However, Borrows described the macro-economic and geopolitical environment as "uncertain", reason for which they were still focusing on actively managing the portfolio and remained cautious on pricing for new investment.

Action, its non-food discount retailer posted a 6.8% jump in its like-for-like sales growth year-to-date with operating profit 16% ahead at €980m.

Royal Sanders meanwhile continued to "perform well".

Audley Travel saw "strong" year-on-year departure performance.

3i Infrastructure's share price increased by 8% during the quarter while Scandlines saw "resilient" trading.

Cash at period end stood at £428m, versus £425m one year before.

As of 1236 BST shares of 3I were off by 2.07% to 4,254.0p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.